Free Trial Information
BioCentury | May 8, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

...Translation in Brief Cardiovascular Myocardial infarction (MI) MicroRNA-19b (miR-19b) Patient sample and mouse studies suggest miR-19a...
Read More
BioCentury | Apr 30, 2019
Distillery Therapeutics

miR-19a and miR-19b and their mimics for myocardial infarction

...DISEASE CATEGORY: Cardiovascular INDICATION: Myocardial infarction (MI) Patient sample and mouse studies suggest miR-19a and miR-19b...
...MI. In heart samples from patients with dilated cardiomyopathy and coronary artery disease, levels of miR-19a...
...steps could include testing the miR-19a and miR-19b mimics in other models of MI. TARGET/MARKER/PATHWAY: MicroRNA-19a (miR-19a)...
Read More
BioCentury | Apr 13, 2015
Company News

Regulus Therapeutics Inc, AstraZeneca deal

Regulus’ partner AstraZeneca selected RG-125 ( AZD4076 ) as the first compound it intends to take into the clinic under the companies’ 2012 deal. AZ plans to start a Phase I trial by year end of the...
Read More
BioCentury | Apr 8, 2015
Company News

AZ picks Regulus' microRNA compound for NASH

Regulus Therapeutics Inc. (NASDAQ:RGLS) gained $1.70 (11%) to $17.65 in early after-hours trading on Tuesday after the company said partner AstraZeneca plc (LSE:AZN; NYSE:AZN) selected RG-125 ( AZD4076 ) as the first compound it intends to take...
Read More
BioCentury | Dec 4, 2014
Distillery Therapeutics

Indication: Inflammation

...asthma, miR-19a expression was higher than that in healthy controls. In a mouse asthma model, miR-19a...
...type 2 cell cytokines, which are associated with disease pathology. Next steps could include testing miR-19a...
Read More
BioCentury | Mar 10, 2014
Company News

Regulus, AstraZeneca deal

Regulus disclosed in its 2013 earnings that it and partner AstraZeneca have selected microRNA-103 (miR-103) and miR-107 as targets under a 2012 deal to develop and commercialize preclinical miRNA therapeutics against three targets focused on...
Read More
BioCentury | Dec 19, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer MicroRNA-17-92 (miR-17-92) Cell culture and mouse studies suggest inhibiting miR-17-92 could help treat medulloblastoma. In a mouse model of medulloblastoma, miRNAs from the...
Read More
BioCentury | Mar 4, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) MicroRNA-19 (miR-19); phosphoinositide 3-kinase (PI3K); protein kinase B (PKB; Akt) In vitro and mouse studies suggest that antagonizing miR-19 could help...
Read More
BioCentury | Sep 18, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Ataxia MicroRNA-19 (miRNA-19); miRNA-101; miRNA-130; ataxin 1 (ATXN1) Cell-culture studies suggest that enhancing the activity of miRNA-19, miRNA-101 and miRNA-130 could...
Read More
BioCentury | Aug 28, 2008
Distillery Therapeutics

This Week in Therapeutics

...therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) microRNA-19a...
Read More
Items per page:
1 - 10 of 11